Lava Therapeutics B.V.

LVTX56

Penny Stock

$1.65arrow_drop_up0.60%$0.01

Penny Stock

LVTX56

$1.65

arrow_drop_up0.60%$0.01

Penny Stock

Performance History

Key Stats
Open	$1.64
Prev. Close	$1.63
EPS	-0.89
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$42.86M
PE Ratio	-

	LOW	HIGH
Day Range	1.61	1.71
52 Week Range	1.13	6.47

Ratios







EPS	-0.89

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Lava Therapeutics B.V. (LVTX)

Lava Therapeutics B.V. (LVTX) is a biotechnology company that specializes in the development of next-generation T-cell therapies for the treatment of cancer. The company's innovative approach is based on the use of its proprietary platform technology, which allows for the generation of highly specific and potent T-cell receptors (TCRs). These engineered TCRs are designed to target and destroy cancer cells, while sparing healthy cells. By harnessing the power of the immune system, Lava Therapeutics aims to provide patients with more effective and less toxic treatment options.

One of the key strengths of Lava Therapeutics is its experienced team of scientists and researchers. The company has assembled a world-class team that includes experts in immunology, oncology, and cell therapy. This multidisciplinary approach allows Lava Therapeutics to tackle the complex challenges of developing T-cell therapies with precision and efficiency. The company's strong scientific foundation has been instrumental in advancing its lead product candidates and attracting partnerships with leading pharmaceutical companies.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Stephen Allen Hurly M.B.A., M.Sc.
Headquarters: Utrecht
Employees: 69
Exchange: NASDAQ

Keep an eye on Lava Therapeutics B.V.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Lava Therapeutics B.V.'s (LVTX) price per share?

The current price per share for Lava Therapeutics B.V. (LVTX) is $1.65. The stock has seen a price change of $0.01 recently, indicating a 0.61% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Lava Therapeutics B.V. (LVTX)?

For Lava Therapeutics B.V. (LVTX), the 52-week high is $6.47, which is 292.12% from the current price. The 52-week low is $1.13, the current price is 45.89% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Lava Therapeutics B.V. (LVTX) a growth stock?

Lava Therapeutics B.V. (LVTX) has shown an average price growth of 0.41% over the past three years. It has received a score of 28 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Lava Therapeutics B.V. as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Lava Therapeutics B.V. (LVTX) stock price performance year to date (YTD)?

As of the latest data, Lava Therapeutics B.V. (LVTX) has a year-to-date price change of -5.87%. Over the past month, the stock has experienced a price change of -10.33%. Over the last three months, the change has been -14.95%. Over the past six months, the figure is -55.53%.

help

Is Lava Therapeutics B.V. (LVTX) a profitable company?

Lava Therapeutics B.V. (LVTX) has a net income of -$41.7M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 48.56% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -371.48% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $6.77M, although specific revenue growth data is currently not available. The gross profit is $3.29M. Operating income is noted at -$43.25M. Furthermore, the EBITDA is -$26.88M.

help

What is the market capitalization of Lava Therapeutics B.V. (LVTX)?

Lava Therapeutics B.V. (LVTX) has a market capitalization of $45.18M. The average daily trading volume is 46.4K, indicating the stock's liquidity and investor engagement.